India to Kenya: Artesunate Export Trade Route

To import Artesunate formulations into Kenya, the following approvals and registrations are mandatory:

• Product Registration: All pharmaceutical products must be registered with the PPB before importation. The registration process involves submitting a comprehensive dossier detailing the product's quality, safety, and efficacy.

• Dossier Format: The PPB requires the Common Technical Document (CTD) format for submissions.

• Timelines for Approval: The approval process duration can vary; however, applicants should anticipate a period of several months, depending on the completeness of the submission and the PPB's review workload.

• Product Registration Fees: Specific fees are associated with the registration process.

• Good Manufacturing Practice (GMP) Inspection: The PPB mandates GMP inspections for manufacturing facilities supplying pharmaceutical products to Kenya. Indian manufacturers must ensure their facilities comply with GMP standards recognized by the PPB.

Indian exporters of Artesunate formulations must adhere to the following quality and GMP standards:

• GMP Certification: Manufacturers must possess GMP certification that aligns with international standards.

• PPB Approval: Manufacturing facilities must be approved by the PPB, confirming compliance with Kenyan regulatory requirements.

• Recent Inspections and Regulatory Actions: As of January 18, 2025, the PPB issued a directive prohibiting the importation, distribution, sale, or handling of pharmaceutical products referencing the Indian Pharmacopoeia (IP). This action underscores the necessity for Indian exporters to ensure their products comply with Kenyan standards and are duly registered with the PPB. (kenyans.co.ke)

In the past 18 months, several regulatory changes have impacted Indian pharmaceutical exports to Kenya:

• January 18, 2025: The PPB banned the importation and sale of pharmaceutical products citing the Indian Pharmacopoeia, emphasizing that such products are not compliant with Kenyan regulations. (kenyans.co.ke)

• February 6, 2026: The PPB announced that 22% of health products circulating in Kenya in 2025 were deemed non-compliant due to the failure of manufacturers or marketing authorization holders to submit renewal applications by the December 31, 2025, deadline. This highlights the importance of timely compliance with registration renewal requirements. (peopledaily.digital)

These developments underscore the PPB's commitment to ensuring that all pharmaceutical products in Kenya meet stringent quality, safety, and efficacy standards. Indian exporters must stay informed of regulatory changes and ensure full compliance to maintain market access.

As of 2025, the global market for Artesunate tablets was valued at approximately USD 850 million, with projections indicating growth to USD 1.32 billion by 2033, reflecting a compound annual growth rate (CAGR) of 6.5%. While specific data for Kenya is limited, the country's demand for Artesunate formulations is primarily driven by the high prevalence of malaria, a leading cause of morbidity and mortality. In 2024, Kenya reported over 3 million confirmed malaria cases, underscoring the critical need for effective antimalarial treatments. The government's commitment to universal health coverage and increased healthcare spending further bolster the demand for Artesunate formulations. Kenya relies heavily on imports to meet this demand, with limited domestic manufacturing capacity for such specialized pharmaceutical products.

Under the EAC Common External Tariff, finished pharmaceutical products classified under HS code 30049059, including Artesunate formulations, are subject to a 0% import duty rate. This exemption is designed to facilitate access to essential medicines. Additionally, imports are subject to a 16% Value Added Tax (VAT), a 3.5% Import Declaration Fee (IDF), and a 2% Railway Development Levy (RDL). There are no specific Free Trade Agreements (FTAs) between India and Kenya that further affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on these imports.

India is the predominant supplier of Artesunate formulations to Kenya, accounting for 18.8% of India's total Artesunate formulation exports, valued at $32.3 million USD across 921 shipments from 82 Indian manufacturers/exporters. The top Indian exporters include AFROWAY PHARMA ($14.7M) and IPCA LABORATORIES LIMITED ($3.8M). The primary buyers in Kenya are THE MANAGER ($12.6M) and the NATIONAL MEDICAL STORES ($2.6M). While other countries, such as China and various European Union manufacturers, also supply Artesunate formulations to Kenya, India's share remains dominant. Indian suppliers are known for offering competitive pricing compared to their Chinese and European counterparts, contributing to their significant market share in Kenya's pharmaceutical imports.

India is a leading global supplier of generic pharmaceuticals, accounting for approximately 20% of the world's generic drug volume. This extensive production capacity is supported by over 3,000 pharmaceutical companies and more than 10,500 manufacturing facilities. As of 2024, India hosts 752 FDA-approved plants, 2,050 WHO-GMP-certified facilities, and 286 EDQM-approved sites, underscoring its commitment to quality and regulatory compliance.

The country's cost-efficient production methods, coupled with a skilled workforce, enable the manufacturing of high-quality Artesunate formulations at competitive prices. This combination of scale, quality, and affordability positions India as a preferred source for Artesunate formulations globally.

India's Artesunate formulations are recognized for their cost-effectiveness and adherence to stringent quality standards. The country supplies nearly 20% of the global generic drug volume and around 40% of the U.S. generic market, reflecting its strong export market worth US$ 27.9 billion in FY 2023–2024. This extensive export experience ensures that Indian manufacturers are well-versed in meeting diverse regulatory requirements, including those of Kenya.

In contrast, while China is a significant producer of generic pharmaceuticals, concerns have been raised regarding regulatory compliance and quality control in some instances. The European Union, known for its high-quality branded generics, often comes with higher costs due to stringent regulatory processes and higher production expenses. Local manufacturers in Kenya may face challenges related to scale and cost-efficiency, making it difficult to compete with the economies of scale achieved by Indian producers.

India's pharmaceutical industry has demonstrated a strong track record of supply reliability. The country operates over 3,000 pharmaceutical companies and more than 10,500 manufacturing facilities, ensuring substantial manufacturing capacity for finished dosage forms. Additionally, India's pharmaceutical sector has seen significant improvements in compliance outcomes over the past several years, indicating a commitment to maintaining high standards.

While there have been isolated instances of regulatory scrutiny, such as Sun Pharma's investment in a new manufacturing facility in Madhya Pradesh to address FDA compliance issues, the overall industry trend indicates a commitment to maintaining high standards. Major manufacturers continue to invest in capacity expansion and technological advancements to meet global demand, ensuring a stable supply chain for Artesunate formulations.

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Artesunate formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear communication with potential suppliers to understand their specific requirements and negotiate terms that align with your procurement needs.

• Payment Terms: Standard payment terms in India-Kenya pharmaceutical trade often include letters of credit or advance payments. It's advisable to negotiate terms that balance financial security with cash flow considerations.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications (such as WHO-GMP and FDA approvals), and assessment of quality control systems to ensure compliance with international standards.

• Regulatory Compliance: Ensure that selected suppliers have a strong track record of regulatory compliance and can provide documentation to support their adherence to quality standards.

By following these recommendations, buyers in Kenya can establish a reliable and cost-effective supply chain for Artesunate formulations sourced from India.

1. Verify Product Registration with the Pharmacy and Poisons Board (PPB): Confirm that the Artesunate formulations are registered with Kenya's PPB. This ensures compliance with local regulatory standards and legal market entry.

2. Assess Good Manufacturing Practice (GMP) Certification Validity: Obtain the supplier's GMP certificate issued by the Central Drugs Standard Control Organization (CDSCO) in India. Ensure the certificate is current and covers the specific manufacturing site producing the Artesunate formulations.

3. Review the Drug Master File (DMF): Request the DMF for the Artesunate formulations to evaluate detailed information on the manufacturing process, controls, and quality standards.

4. Evaluate Quality Management Systems: Confirm that the supplier has a robust Quality Management System (QMS) in place, adhering to international standards such as ISO 9001. This includes procedures for quality control, assurance, and continuous improvement.

5. Confirm Minimum Acceptable Certifications: Ensure the supplier holds certifications like WHO-GMP, which indicates compliance with international pharmaceutical manufacturing standards.

6. Assess Regulatory Compliance History: Investigate the supplier's history for any regulatory actions, such as recalls or warning letters, to gauge their compliance track record.

7. Review Stability Data for ICH Climatic Zones III and IV: Obtain stability data demonstrating that the Artesunate formulations maintain efficacy and safety under the climatic conditions prevalent in Kenya.

8. Evaluate Supply Chain and Logistics Capabilities: Assess the supplier's ability to deliver products reliably, considering factors like lead times, shipping methods, and storage conditions.

9. Conduct Financial Due Diligence: Review the supplier's financial stability to ensure they can sustain long-term supply commitments.

10. Plan for On-Site Audits: Arrange for an on-site audit of the manufacturing facility to verify compliance with GMP and other quality standards.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies that the Artesunate formulations were manufactured in India, which may be required for customs and regulatory purposes.

3. Good Manufacturing Practice (GMP) Certificate: Issued by CDSCO, this certificate confirms that the manufacturing facility complies with GMP standards.

4. Stability Data: Demonstrates that the product maintains its quality over time under various environmental conditions, particularly those relevant to Kenya's climate.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Contains comprehensive information on the manufacturing process, controls, and quality standards of the Artesunate formulations.

7. Free Sale Certificate: Issued by CDSCO, this certificate indicates that the product is approved for sale in India, suggesting compliance with local regulatory standards.

8. Insurance Certificates: Proof of insurance coverage for product liability, ensuring protection against potential claims related to product quality or safety.

1. Recent Regulatory Actions: Suppliers with recent warning letters or sanctions from regulatory bodies such as the U.S. FDA or WHO-GMP suspensions may indicate compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates can suggest potential compromises in quality or sourcing of substandard materials.

3. Lack of Stability Data: Inability to provide stability data, especially for ICH Climatic Zones III and IV, raises concerns about the product's efficacy in Kenya's climate.

4. No Export Track Record to African Markets: Suppliers without a history of exporting to Africa may lack experience in meeting regional regulatory and quality requirements.

5. Resistance to Factory Audits: Hesitance or refusal to allow on-site inspections can indicate potential compliance or quality issues.

6. Inconsistent Documentation: Discrepancies or incomplete information in provided documents may reflect poor quality control or attempts to conceal deficiencies.

1. Pre-Audit Desktop Review: Analyze all provided documentation, including GMP certificates, CoAs, and stability data, to identify potential areas of concern before the on-site audit.

3. Post-Audit Corrective Action Expectations: Require the supplier to address any identified deficiencies within a specified timeframe, providing evidence of corrective actions taken.

4. Annual Re-Qualification Process: Implement a yearly review of the supplier's compliance and performance, including updated audits and documentation reviews.

5. Remote Monitoring Options: Utilize virtual audits, regular video conferences, and electronic document reviews to maintain oversight between on-site visits.

Cost Estimates and Timeline for Audit Visits to India:

• Cost Estimates:
• Travel Expenses:
• Approximately $2,000–$3,000 per auditor, covering flights, accommodation, and meals.
• Audit Fees:
• Professional fees ranging from $1,500–$2,500 per day, depending on the audit's complexity and duration.

• Timeline:
• Planning and Preparation:
• 2–4 weeks to coordinate with the supplier and arrange logistics.
• On-Site Audit:
• Typically 2–3 days, depending on the facility's size and complexity.
• Post-Audit Reporting:
• 1–2 weeks to compile findings and communicate corrective actions required.

By adhering to this comprehensive approach, Kenya buyers can ensure the selection of reliable and compliant Indian suppliers for Artesunate formulations, safeguarding public health and maintaining regulatory compliance.